Franklin Street Advisors Inc. NC Buys 100,000 Shares of FibroGen, Inc. (NASDAQ:FGEN)

Franklin Street Advisors Inc. NC grew its stake in shares of FibroGen, Inc. (NASDAQ:FGEN) by 100.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200,000 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the period. Franklin Street Advisors Inc. NC’s holdings in FibroGen were worth $106,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC boosted its holdings in shares of FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares in the last quarter. JPMorgan Chase & Co. increased its position in FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares in the last quarter. AQR Capital Management LLC raised its stake in FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares during the last quarter. Geode Capital Management LLC boosted its holdings in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in FibroGen during the 3rd quarter valued at about $307,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. StockNews.com started coverage on FibroGen in a research note on Wednesday, January 1st. They issued a “hold” rating for the company. HC Wainwright raised shares of FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th. Finally, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Down 1.7 %

NASDAQ:FGEN traded down $0.01 on Friday, hitting $0.64. The stock had a trading volume of 1,523,068 shares, compared to its average volume of 2,034,973. The business’s 50-day simple moving average is $0.42 and its two-hundred day simple moving average is $0.51. The stock has a market cap of $64.46 million, a price-to-earnings ratio of -0.52 and a beta of 0.75. FibroGen, Inc. has a 52-week low of $0.18 and a 52-week high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the previous year, the firm earned ($0.52) EPS. As a group, equities research analysts anticipate that FibroGen, Inc. will post -0.86 EPS for the current year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.